Current Share Price data for TruScreen Group Limited (NZX:TRU ASX:TRU)
Cervical cancer can and should be prevented.
TruScreen provides an accurate, real-time primary screening solution.
Our screening solution is ideal for communities that can’t access conventional laboratory-based screening methods. It is affordable and easy to learn.
Our purpose is to ensure that all women of screening age – no matter who or where they are – have access to quality screening.
TruScreen manufactures and owns all rights to the TruScreen Cervical Cancer Screening System. The system comprises a medical device and AI-enabled process designed to detect, in real-time, the presence of pre-cancerous and cancerous tissue on the cervix.
TruScreen’s focus markets are low and-middle income countries (LMICs) where there is a lack of organised cervical cancer screening and the required infrastructure.
Pitt Street Research
7.3.2023
TruScreen Group Ltd (NZX/ASX: TRU) is a medtech company that is commercialising the TRU system.
GENERAL
13.3.2023
Truscreen Group Limited is pleased to advise that the leading private medical services provider , Dr. Sulaiman Al-Habib Medical Group, has recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC).
GENERAL
8.3.2023
Truscreen Group Limited is pleased to advise that its China distributor has placed an order for 40 TruScreen cervical cancer screening devices for installation into China’s growing public Health Check Sector. Delivery is expected in April 2023.
OFFER
3.3.2023
Truscreen Group Limited is pleased to advise that further to the announcement of 17 February 2023 “Truscreen to lodge a pro rata renounceable rights issue”, the Company has received firm commitments from a number of investors for an initial Placement of 20,000,000 shares at NZ$0.03 each to raise $600,000, before costs.
OFFER
28.2.2023
Truscreen Group Limited announced its intention to launch a 1 for 5 pro-rata renounceable rights issue to raise up to circa $2.2 million ("Rights Offer”) on 17 February 2023.
OFFER
24.2.2023
Further to the announcement on 17 February 2023 in relation to a Pro Rata Renounceable Rights Issue, TruScreen is pleased to provide the Offer Document, attached to this announcement.
OFFER
17.2.2023
Notice of Offer of Same Class Financial Products for Issue. Truscreen Group Limited intends to undertake an offer of new ordinary shares in TRU by way of a pro-rata 1 for 5 renounceable rights offer to eligible shareholders followed by an Oversubscription Bookbuild Facility process.
OFFER
17.2.2023
A Corporate Action Notice relating to a Pro Rata Renounceable Rights Issue is attached.
OFFER
17.2.2023
TruScreen Group Limited is pleased to announce its intention to launch a one (1) for five (5) pro-rata renounceable rights issue to raise up to circa NZD$2.2 million ("Rights Offer”).
GENERAL
15.2.2023
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this commercial update.
GENERAL
19.12.2022
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide this update on Distributor progress in November/ December 2022.
HALFYR
Template Results announcement - for Equity Security issuer/Equity and Debt Security issuer
HALFYR
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company), is pleased to provide its unaudited financial results for the six months to 30 September 2022 (1H FY23), along with the following operational update. TruScreen reports according to the New Zealand financial year, which runs from 1 April to 31 March.
GENERAL
Cervical cancer screening technology company, TruScreen Group Limited (NZX/ASX: TRU), is pleased to provide this market update which includes commentary on its unaudited financial results for the six months to 30 September 2022 (1H FY23).
GENERAL
9.11.2022
Truscreen Limited is pleased to provide a copy of its November 2022 Stakeholders Newsletter. This gives an updated on TruScreen's performance and highlights key initiatives underway.
GENERAL
2.11.2022
Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce successful completion of the first global virtual medical symposium to key opinion leaders from 7 countries, on cervical cancer screening.
GENERAL
6.10.2022
Truscreen Group Limited (NZX/ASX:TRU) is pleased to announce the appointment of Dr. Beata Edling as Chief Executive Officer.
GENERAL
1.9.2022
TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that it has executed a five-year manufacturing contract with its current critical supplier, Zapco International Limited, for the manufacture and supply of Single Use Sensors.
GENERAL
10.8.2022
TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce that its China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.
GENERAL
3.8.2022
TruScreen Group Limited (NZX/ASX: TRU) is pleased to announce the establishment of a TruScreen-based cervical cancer screening centre in a new clinic in Cludad de Mexico (Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical.
GENERAL
5.4.2022
COGA Trial screened 15,661 women across 64 hospitals in 9 provinces over 3 years. TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV. TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
TruScreen Group is dual-listed on the NZX and ASX. All of our announcements are available through our website, or via the NZX and ASX platforms.
View announcementsTruScreen has a wealth of experienced, highly skilled professionals across its Directors, Executive Team, Medical Advisory Board, and Research & Development Team.